L-NAME promotes foam cell formation and synthetic phenotype marker changes in vascular smooth muscle cells independent of hemodynamic effects

Du, Huanhua, Ling, Jia, Lu, Zheng, Liu, Yutong, Yan, Jinsong, Ma, Junli, Li, Li, Chen, Gang
BMC Molecular and Cell Biology · Springer Nature · 2026-07-13 · DOI: 10.1186/s12860-026-00600-z

Abstract

Objective This study investigated whether L-NAME, a nitric oxide synthase (NOS) inhibitor commonly used to model hypertension-associated endothelial dysfunction, can exert direct pro-atherogenic effects on vascular smooth muscle cells (VSMCs) independent of systemic hemodynamic influences. Methods Mouse aortic VSMCs (MOVAS) were treated with non-cytotoxic concentrations of L-NAME (50 µM) or oxidized low-density lipoprotein (ox-LDL, 100 µg/mL), which served as a positive atherogenic control. Lipid accumulation was assessed by Oil Red O staining. The expression of contractile phenotype markers (ACTA2, MYH11, and α-SMA), the synthetic phenotype marker SPP1, and matrix metalloproteinases (MMP-2 and MMP-9) was quantified by qRT-PCR and immunofluorescence. Results Both L-NAME and ox-LDL treatments caused marked intracellular lipid accumulation in MOVAS cells, consistent with VSMC-derived foam cell formation. L-NAME and ox-LDL reduced the mRNA expression of contractile phenotype markers (ACTA2 and MYH11, p < 0.05) and decreased α-SMA protein expression ( p < 0.001). Conversely, both treatments increased the mRNA expression of the synthetic phenotype marker SPP1 ( p < 0.05) and matrix-remodeling genes MMP-2 and MMP-9 ( p < 0.05). These effects were directionally similar to those induced by ox-LDL. Conclusion L-NAME directly promotes lipid accumulation and synthetic phenotype-associated marker changes in MOVAS cells under the present in vitro conditions. Because eNOS/NOS activity, intracellular NO levels, rescue pathways, and primary VSMC validation were not assessed, these data should be interpreted as phenotypic evidence that NOS/NO pathway disruption may contribute to VSMC dysfunction rather than definitive proof of a single eNOS-dependent mechanism. Clinical trial number Not applicable.

Read at publisher →

Similar articles